Technical Analysis for RVX - Resverlogix Corp.

Grade Last Price % Change Price Change
grade F 2.57 -4.81% -0.130
RVX closed down 4.81 percent on Tuesday, September 17, 2019, on 2.14 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical RVX trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -4.81%
50 DMA Resistance Bearish -4.81%
Volume Surge Other -4.81%

Older signals for RVX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Resverlogix Corp. is a clinical-stage biotechnology company. The Company is a development-stage company, which is engaged in developing apabetalone (RVX-208), a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer's disease and orphan diseases. Apabetalone is being investigated in a Phase III clinical trial for the secondary prevention of major adverse cardiovascular events (MACE) in high risk patients with diabetes mellitus and chronic kidney disease. The Company initiated a Phase III clinical trial BETonMACE with apabetalone in high-risk cardiovascular disease patients with low high-density lipoprotein. It focuses on conducting a proof-of-concept clinical trial in patients with Paroxysmal Nocturnal Hemoglobinuria. The Company has not generated any revenues.
Medicine Medical Specialties Biotechnology RTT Alzheimer's Disease Chronic Condition Diabetes Mellitus
Is RVX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 4.94
52 Week Low 2.57
Average Volume 54,973
200-Day Moving Average 3.2011
50-Day Moving Average 2.8448
20-Day Moving Average 2.837
10-Day Moving Average 2.771
Average True Range 0.1391
ADX 11.05
+DI 15.5695
-DI 20.9613
Chandelier Exit (Long, 3 ATRs ) 2.6227
Chandelier Exit (Short, 3 ATRs ) 2.9873
Upper Bollinger Band 3.0348
Lower Bollinger Band 2.6392
Percent B (%b) -0.17
BandWidth 13.944307
MACD Line -0.0501
MACD Signal Line -0.0249
MACD Histogram -0.0252
Fundamentals Value
Market Cap 294.58 Million
Num Shares 115 Million
EPS -0.52
Price-to-Earnings (P/E) Ratio -4.94
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.885
Resistance 3 (R3) 2.920 2.850 2.833
Resistance 2 (R2) 2.850 2.770 2.833 2.815
Resistance 1 (R1) 2.710 2.720 2.675 2.675 2.797
Pivot Point 2.640 2.640 2.623 2.623 2.640
Support 1 (S1) 2.500 2.560 2.465 2.465 2.343
Support 2 (S2) 2.430 2.510 2.413 2.325
Support 3 (S3) 2.290 2.430 2.308
Support 4 (S4) 2.255